Tom20 senses iron-activated ROS signaling to promote melanoma cell pyroptosis.
Zhou B, Zhang JY, Liu XS, Chen HZ, Ai YL, Cheng K, Sun RY, Zhou D, Han J, Wu Q. · 2018
Read Tom20 senses iron-activated ROS signaling to promote melanoma cell pyroptosis. by Zhou B, Zhang JY, Liu XS, Chen HZ, Ai YL, Cheng K, Sun RY, Zhou D, Han J, Wu Q. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6274649.txt.
Introduction
Zhou and co-authors found a new path by which iron helps kill melanoma cells. Their study appeared in Cell Research. Iron raises reactive oxygen species, which can drive several death forms. Whether it could drive pyroptosis, a fiery cell death, was unknown. Melanoma cells carry high levels of a key pore protein for that death. That trait made them a good test case.
Iron boosted oxygen signals started by a stress drug. A mitochondrial protein called Tom20 sensed those signals and clumped together. It then drew in Bax, which freed signals that switched on a cutting enzyme. That enzyme split the pore protein, and the cells died by pyroptosis. Adding iron at patient level doses boosted standard drugs in mouse tumours. Growth and spread both slowed, with no clear harm to normal organs.
Catalog record
| CREATOR | Zhou B, Zhang JY, Liu XS, Chen HZ, Ai YL, Cheng K, Sun RY, Zhou D, Han J, Wu Q. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 74 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Tom20 senses iron-activated ROS signaling to promote melanoma cell pyroptosis By Bo Zhou, Jia-yuan Zhang, Xian-shuo Liu, Hang-zi Chen, Yuan-li Ai, Kang Cheng, Ru-yue Sun, Dawang Zhou, Jiahuai Han, Qiao Wu Published in: Cell Research DOI: 10.1038/s41422-018-0090-y ABSTRACT Iron has been shown to trigger oxidative stress by elevating reactive oxygen species (ROS) and to participate in different modes of cell death, such as ferroptosis, apoptosis and necroptosis. However, whether iron-elevated ROS is also linked to pyroptosis has not been reported. Here, we demonstrate that iron-activated ROS can induce pyroptosis via a Tom20-Bax-caspase-GSDME pathway. In melanoma cells, iron enhanced ROS signaling initiated by CCCP, causing the oxidation and oligomerization of the mitochondrial outer membrane protein Tom20. Bax is recruited to mitochondria by oxidized Tom20, which facilitates cytochrome c release to cytosol to activate caspase-3, eventually triggering pyroptotic death by inducing GSDME cleavage. Therefore, ROS acts as a causative factor and Tom20 senses ROS signaling for iron-driven pyroptotic death of melanoma cells. Since iron activates ROS for GSDME-dependent pyroptosis induction and melanoma cells specifically express a high level of GSDME, iron may be a potential candidate for melanoma therapy. Based on the functional mechanism of iron shown above, we further demonstrate that iron supplementation at a dosage used in iron-deficient patients is sufficient to maximize the anti-tumor effect of clinical ROS-inducing drugs to inhibit xenograft tumor growth and metastasis of melanoma cells through GSDME-dependent pyroptosis. Moreover, no obvious side effects are observed in the normal tissues and organs of mice during the combined treatment of clinical drugs and iron. This study not only identifies iron as a sensitizer amplifying ROS signaling to drive pyroptosis, but also implicates a novel iron-based intervention strategy for melanoma therapy. INTRODUCTION Reactive oxygen species (ROS) have been reported to be associated with cancer development and cancer cell death. At low to moderate levels, ROS promote tumor development by inducing DNA mutations and genomic instability or acting as signaling molecules that accelerate cancer cell proliferation, survival and metastasis.1,2 In contrast, excessive levels of ROS enhance cellular oxidative stress, which causes damage to DNA, proteins or lipids, leading to apoptotic or necroptotic cell death.3,4 For example, following treatment of apoptotic stimuli, the ROS-initiated oxidation of cardiolipin, which is a lipid located on the inner mitochondrial membrane, results in cytochrome c release, caspase activation and apoptotic cell death.5 Receptor-interacting protein kinase 3 (RIP3)-induced mitochondrial ROS generation leads to necroptosis in response to TNF-α stimulation.6,7 Therefore, boosting ROS in cancer cells by chemotherapeutic drugs has been applied in clinical cancer therapy.2 There are numerous ROS sources in cells, including iron-dependent ROS activation. First, iron is an essential component of several ROS-producing enzymes, such as NADPH oxidases (NOXs), lipoxygenases (LOXs), cytochrome P450 (CYP) enzymes and the mitochondrial electron transport chain subunits.4 Second, labile iron pools in cells directly catalyze ROS generation via the Fenton reaction.4 In most cells, excessive intracellular iron is stored in ferritin, where iron is safely sequestrated from being involved in ROS generation reactions.8 Ferritin comprises two subunits, the ferritin heavy chain (FTH) and ferritin light chain (FTL). The disruption of ferritin results in the elevation of ROS and cell death in an iron-dependent manner.9,10 Due to the important role of iron in the elevation of oxidative stress, targeting iron has emerged as a potential cancer therapy.4 However, the mechanism by which iron-induced ROS promote cell death remains ambiguous. Apoptosis, necroptosis and ferroptosis have been shown to be associated with iron-triggered cell death via the ROS pathway,11 suggesting that iron likely plays a role in ROS signaling. Here, we further demonstrate that iron induces another type of cancer cell death, pyroptosis. Pyroptosis is a form of lytic programmed cell death initiated by inflammasomes, which activate caspase-1 or caspase-11/4/5 to cleave gasdermin D (GSDMD). The N-terminal pore-forming domain (PFD) of GSDMD oligomerizes to form nonselective pores in the membrane that drive cell swelling and membrane rupture.12–15 Recently, GSDME (original name: deafness autosomal dominant 5, DFNA516) was also reported to be involved in pyroptosis induction. Following treatment with certain apoptotic stimuli, activated caspase-3 cleaves GSDME to release its PFD for pore formation, consequently triggering secondary necrosis after apoptosis or pyroptosis.17,18 Despite the well-known anti-infection effect of pyroptosis in immune cells, whether the induction of pyroptosis could be adopted in cancer therapy remains unclear. Melanoma is among the most aggressive human cancers.19 Due to genetic or epigenetic alterations, melanoma cells are resistant to apoptotic induction.20,21 Therefore, developing new strategies for melanoma therapy is important. We previously reported that the induction of autophagic cell death by the small-molecule compound THPN could be an option for melanoma treatment.22,23 Here, we further combined iron with ROS-inducing drugs that can boost the cellular ROS level to activate the Tom20-Bax-caspase-GSDME signaling pathway and ultimately induce the pyroptotic death of melanoma cells. This antineoplastic effect of iron was further verified in mouse models. Collectively, our study illuminates that iron-based pyroptosis induction may be a novel, promising therapeutic strategy for the clinical treatment of melanoma. RESULTS Iron boosts ROS to induce pyroptosis in melanoma cells Iron is an essential factor for body homeostasis and participates in the regulation of cell survival. It has been previously reported that iron storage protein ferritin contributes to the melanoma progression by modulating cell growth and sensitivity to oxidative stress.24 Based on this finding, ferritin light chain protein (FTL) or ferritin heavy chain 1 (FTH1), two components of ferritin, was separately knocked down in melanoma A375 cells (Supplementary information, Fig. S1a), and several reagents that activate oxidative stress, including carbonyl cyanide m-chlorophenyl hydrazone (CCCP),25 NaAsO2,26 H2O2, antimycin A,27 and oligomycin,28 were used to evaluate the role of iron metabolism in cell death. Although these reagents hardly influenced A375 cell survival, they induced cell death in the FTL- or FTH1-knockdown A375 cells (Supplementary information, Fig. S1b). Among these compounds, we noted that CCCP treatment was not only most effective in cell death induction, but also obviously induced the characteristic morphological features of pyroptosis, as evidenced by cell swelling, large bubbles blowing from the plasma in the FTL- or FTH1-knockdown A375 cells (Supplementary information, Fig. S1c, pyroptotic cells were indicated by red arrows). Therefore, it is likely that CCCP may specifically induce melanoma cell death through pyroptosis when endogenous ferritin is disrupted. To confirm the requirement of endogenous iron for pyroptosis in the FTH1- or FTL-knockdown A375 cells, cells were pretreated with deferoxamine (DFO, an iron chelating agent) before CCCP stimulation. Under this circumstance, CCCP-induced morphology of pyroptosis and release of lactate dehydrogenase (LDH, an indication of pyroptotic cell cytotoxicity) were remarkably attenuated (Supplementary information, Fig. S1d), which illustrates the involvement of endogenous iron in CCCP-induced pyroptosis. We further determined whether this CCCP-induced pyroptosis is directly associated with iron overload. A375 cells were treated with CCCP plus exogenous iron (FeSO4 in the current study) without knocking down FTH1 or FTL. Co-treatment of CCCP/iron showed more pronounced inhibition in cell survival accompanied with significant pyroptosis and LDH release, as compared to CCCP treatment alone (Fig. 1a; Supplementary information, Movie S1). Notably, the effects of exogenous iron on LDH release and cell death were more evident in the FTH1- or FTL-knockdown A375 cells (Fig. 1b). Therefore, blocking ferritin would facilitate iron to exert its function in driving melanoma